Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H2 2017’, provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

The report reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics and enlists all their major and minor projects

The report assesses Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Amgen Inc

arGEN-X BV

Biogen Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CSL Ltd

Dova Pharmaceuticals Inc

Enzene Biosciences Ltd

Genosco Inc

GlaxoSmithKline Plc

Hansa Medical AB

Immunomedics Inc

Intas Pharmaceuticals Ltd

Jiangsu Hengrui Medicine Co Ltd

Momenta Pharmaceuticals Inc

Novartis AG

Pfizer Inc

Pharmagenesis Inc

Protalex Inc

Rigel Pharmaceuticals Inc

UCB SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview 6

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 11

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment 14

Assessment by Target 14

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development 22

3SBio Inc 22

Amgen Inc 22

arGEN-X BV 23

Biogen Inc 23

Boehringer Ingelheim GmbH 24

Bristol-Myers Squibb Company 24

CSL Ltd 25

Dova Pharmaceuticals Inc 25

Enzene Biosciences Ltd 26

Genosco Inc 26

GlaxoSmithKline Plc 27

Hansa Medical AB 27

Immunomedics Inc 28

Intas Pharmaceuticals Ltd 28

Jiangsu Hengrui Medicine Co Ltd 29

Momenta Pharmaceuticals Inc 30

Novartis AG 31

Pfizer Inc 32

Pharmagenesis Inc 32

Protalex Inc 33

Rigel Pharmaceuticals Inc 33

UCB SA 34

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Drug Profiles 35

avatrombopag - Drug Profile 35

belimumab - Drug Profile 38

BI-655064 - Drug Profile 46

efgartigimod alfa - Drug Profile 48

eltrombopag olamine - Drug Profile 51

eltrombopag olamine - Drug Profile 58

fostamatinib disodium - Drug Profile 59

GL-2045 - Drug Profile 65

Hetrombopag Olamine - Drug Profile 67

KLM-465 - Drug Profile 68

letolizumab - Drug Profile 70

M-230 - Drug Profile 71

M-254 - Drug Profile 72

M-281 - Drug Profile 73

PBF-1650 - Drug Profile 74

PHN-013 - Drug Profile 75

PRTX-100 - Drug Profile 76

Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 83

rituximab - Drug Profile 84

romiplostim - Drug Profile 91

romiplostim biosimilar - Drug Profile 95

romiplostim biosimilar - Drug Profile 96

rozanolixizumab - Drug Profile 97

SKIO-703 - Drug Profile 98

thrombopoietin - Drug Profile 100

veltuzumab - Drug Profile 101

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects 105

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products 106

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones 107

Featured News & Press Releases 107

Appendix 117

Methodology 117

Coverage 117

Secondary Research 117

Primary Research 117

Expert Panel Validation 117

Contact Us 117

Disclaimer 118

List of Tables

List of Tables

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by 3SBio Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Amgen Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by arGEN-X BV, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Biogen Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Boehringer Ingelheim GmbH, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Bristol-Myers Squibb Company, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by CSL Ltd, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Dova Pharmaceuticals Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Enzene Biosciences Ltd, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Genosco Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by GlaxoSmithKline Plc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Hansa Medical AB, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Immunomedics Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Intas Pharmaceuticals Ltd, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Momenta Pharmaceuticals Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Novartis AG, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Pfizer Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Pharmagenesis Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Protalex Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Rigel Pharmaceuticals Inc, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by UCB SA, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Dormant Projects, H2 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports